Neurosensory retinal detachment due to sunitinib treatment.
作者信息
Wegner A, Khoramnia R
出版信息
Eye (Lond). 2011 Nov;25(11):1517-8. doi: 10.1038/eye.2011.200. Epub 2011 Aug 19.
Abstract
摘要
相似文献
1
Neurosensory retinal detachment due to sunitinib treatment.舒尼替尼治疗导致的神经感觉性视网膜脱离。
Eye (Lond). 2011 Nov;25(11):1517-8. doi: 10.1038/eye.2011.200. Epub 2011 Aug 19.
2
Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma.舒尼替尼治疗晚期肾细胞癌引起的双侧视乳头水肿。
Med Oncol. 2011 Dec;28 Suppl 1:S395-7. doi: 10.1007/s12032-010-9719-5. Epub 2010 Nov 4.
3
4
Home blood-pressure monitoring in patients receiving sunitinib.接受舒尼替尼治疗患者的家庭血压监测。
N Engl J Med. 2008 Jan 3;358(1):95-7. doi: 10.1056/NEJMc072330.
5
Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
Arch Dermatol. 2008 Aug;144(8):1081-2. doi: 10.1001/archderm.144.8.1081.
6
Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib.
Clin Res Cardiol. 2007 Nov;96(11):829-30. doi: 10.1007/s00392-007-0567-z. Epub 2007 Aug 21.
7
Rectal perforation associated with sunitinib therapy.与舒尼替尼治疗相关的直肠穿孔
Rev Esp Enferm Dig. 2013 Jul;105(6):370-1. doi: 10.4321/s1130-01082013000600014.
8
Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.老年男性患者接受舒尼替尼治疗后出现可逆性后部白质脑病综合征。
Br J Clin Pharmacol. 2011 May;71(5):777-9. doi: 10.1111/j.1365-2125.2010.03893.x.
9
Fatigue with sunitinib-induced hypothyroidism.舒尼替尼诱导的甲状腺功能减退伴疲劳。
Lancet Oncol. 2007 Feb;8(2):101. doi: 10.1016/s1470-2045(07)70016-5.
10
The case / progressive hypertension and proteinuria on anti-angiogenic therapy.该病例 / 抗血管生成治疗过程中的进行性高血压和蛋白尿
Kidney Int. 2008 Sep;74(5):685-6. doi: 10.1038/ki.2008.288.
引用本文的文献
1
Side Effects of Novel Anticancer Drugs on the Posterior Segment of the Eye: A Review of the Literature.新型抗癌药物对眼后段的副作用：文献综述
J Pers Med. 2024 Dec 19;14(12):1160. doi: 10.3390/jpm14121160.
2
Vogt-Koyanagi-Harada-Like Disease with Loss of Visual Acuity due to Sunitinib Treatment Restored after Switch in Therapy: A Case Report.舒尼替尼治疗导致视力丧失的类伏格特-小柳-原田病在更换治疗后视力恢复：一例报告
Case Rep Ophthalmol. 2024 Mar 7;15(1):184-188. doi: 10.1159/000536572. eCollection 2024 Jan-Dec.
3
Presumed bilateral diffuse uveal melanocytic proliferation - A case report and review of literature.疑似双侧弥漫性葡萄膜黑素细胞增生——一例病例报告及文献综述
Am J Ophthalmol Case Rep. 2022 May 13;27:101582. doi: 10.1016/j.ajoc.2022.101582. eCollection 2022 Sep.
4
Bilateral rhegmatogenous retinal detachments in a patient taking pazopanib: A case report.一名服用帕唑帕尼的患者发生双侧孔源性视网膜脱离：病例报告。
Am J Ophthalmol Case Rep. 2022 Mar 7;26:101463. doi: 10.1016/j.ajoc.2022.101463. eCollection 2022 Jun.
5
Ocular Toxicity of Targeted Anticancer Agents.靶向抗癌药物的眼部毒性。
Drugs. 2021 May;81(7):771-823. doi: 10.1007/s40265-021-01507-z. Epub 2021 Mar 31.
6
Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy.靶向治疗和免疫检查点抑制剂治疗的眼部毒性的临床诊断和治疗建议。
Thorac Cancer. 2020 Mar;11(3):810-818. doi: 10.1111/1759-7714.13327. Epub 2020 Feb 4.
7
[Clinical Diagnosis and Treatment Recommendations for Ocular Toxicities of Target Therapy and Immune Checkpoint Inhibitor Therapy].[靶向治疗和免疫检查点抑制剂治疗眼部毒性的临床诊断与治疗建议]
Zhongguo Fei Ai Za Zhi. 2019 Oct 20;22(10):653-660. doi: 10.3779/j.issn.1009-3419.2019.10.09.
8
Neuro-ophthalmic side effects of molecularly targeted cancer drugs.分子靶向抗癌药物的神经眼科副作用。
Eye (Lond). 2018 Feb;32(2):287-301. doi: 10.1038/eye.2017.222. Epub 2017 Oct 20.
9
A case of retinal tear associated with use of sorafenib.一例与使用索拉非尼相关的视网膜撕裂。
Front Oncol. 2014 Jul 24;4:196. doi: 10.3389/fonc.2014.00196. eCollection 2014.
10
Ocular toxicity from systemically administered xenobiotics.系统给予的异生物质的眼毒性。
Expert Opin Drug Metab Toxicol. 2012 Oct;8(10):1277-91. doi: 10.1517/17425255.2012.708337. Epub 2012 Jul 18.
本文引用的文献
1
Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.GIST 的靶向治疗：通过积极的治疗管理来预防不良事件并使舒尼替尼的获益最大化。
Acta Oncol. 2010;49(1):13-23. doi: 10.3109/02841860903287205.
2
Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy.玻璃体内注射贝伐单抗治疗慢性中心性浆液性脉络膜视网膜病变。
Eur J Ophthalmol. 2009 Jul-Aug;19(4):613-7. doi: 10.1177/112067210901900415.
3
Central serous chorioretinopathy.中心性浆液性脉络膜视网膜病变
Acta Ophthalmol. 2008 Mar;86(2):126-45. doi: 10.1111/j.1600-0420.2007.00889.x. Epub 2007 Jul 28.
4
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.肾细胞癌中血管内皮生长因子靶向治疗：现状与未来方向
Clin Cancer Res. 2007 Feb 15;13(4):1098-106. doi: 10.1158/1078-0432.CCR-06-1989.
5
Systemic disorders associated with detachment of the neurosensory retina and retinal pigment epithelium.
Curr Opin Ophthalmol. 2000 Dec;11(6):455-61. doi: 10.1097/00055735-200012000-00012.
Zotero 插件